Insider Cluster ·Filed Mar 27, 2026

SLNO

SOLENO THERAPEUTICS INC
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $274K total
Actionable Insight • Neutral

Monitor for follow-up filings or disclosures that may explain the rationale behind these sales; given the small size relative to market cap, this cluster is likely routine and not a strong signal.

DirectionNeutral
Confidencelow
Horizondays
Latest settled — T+20d
SLNO ▲ +75.54% at T+20d
NEUTRAL call ✓ call won +75.54% · α vs SPY +62.80% · entry $30.05 → $52.75
Next anchor: T+60d due 3mo ago
Latest observation: T+35 +69.48% FF3 residual α
Entry anchored
Mar 26, 03:59 PM ET
via exchange tick
T+1d
+1.30%
call +1.30% · α +1.66%
$30.44
settled 6mo ago
T+5d
+73.88%
call +73.88% · α +70.01%
$52.25
settled 6mo ago
T+20d
+75.54%
call +75.54% · α +62.80%
$52.75
settled 5mo ago
T+60d
—
call — · α —
—
due 3mo ago

Price Chart

Loading chart...

Executive Summary

Analysis based on filing metadata only — document content was unavailable. Two insiders at Soleno Therapeutics Inc. (SLNO) conducted open-market sales totaling approximately $274K within the last 7 days, representing a small fraction of the company's $1.6B market cap.

Key Financial Metrics

Direction
selling

Key Facts

  • Filing is an insider trading cluster involving two executives at SLNO.
  • Chief Commercial Officer and Senior VP of Clinical Development each sold shares in late March 2026.
  • Total open-market sales amount to ~$274K, or 0.017% of SLNO's $1.6B market cap.
  • No document content available to assess context or motivation behind trades.

Financial Impact

$274K in open-market sales, or 0.017% of market cap

insider ownershipmarket sentiment

Risk Factors

  • Potential perception of insider lack of confidence, though magnitude is too small to be material
  • Lack of filing content limits ability to assess whether sales are part of a pre-arranged plan or reactive to material non-public information

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

Report based on filing metadata.

10 reports for SLNO
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +29.26%Feb 25, 2026
Filters
Rows
Reports for SLNO — sortable, filterable
TypeNow
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
—awaiting T+1——
Jun 11, 2026
16w ago
Institutional Cluster
MIXED ★ 4/10
—awaiting T+1——
May 28, 2026
18w ago
15-12G
BEARISH ★ 8/10
—awaiting T+1——
May 28, 2026
18w ago
EFFECT
BEARISH ★ 5/10
—awaiting T+1——
May 18, 2026
19w ago
8-K / 25-NSE
BULLISH ★ 8/10
$53.01 $53.01· 0.00%▲ +0.65%—
Apr 7, 2026
25w ago
8-K
BEARISH ★ 7/10
$52.35 $52.60▼ −0.48%▲ +2.06%—
Apr 6, 2026
25w ago
8-K
BULLISH ★ 8/10
$52.25 $52.35▲ +0.19%▲ +0.13%—
Mar 27, 2026
27w ago
Insider Cluster
NEUTRAL ★ 3/10
$30.05 $30.44▲ +1.30%▲ +1.66%—
Feb 26, 2026
31w ago
8-K
NEUTRAL ★ 3/10
$38.09 $39.07▲ +2.57%▲ +3.03%—
Feb 25, 2026
31w ago
8-K
BULLISH ★ 8/10
$41.01 $38.09▼ −7.12%▼ −6.57%—
Showing 10 of 10

US Market Status

Market Open — Closes in 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 1, 2026